Pomerantz Law Firm Calls Attention to Class Action Suit Against uniQure N.V. After Major Investment Losses

Investor Alert: Class Action Lawsuit Filed Against uniQure N.V.

The Pomerantz Law Firm has recently announced a significant development for investors in uniQure N.V., a company listed on NASDAQ under the ticker symbol QURE. This comes in light of a class action lawsuit that has been initiated, allowing investors who have sustained losses to seek justice and potential compensation.

The lawsuit primarily addresses allegations of securities fraud and unlawful business practices purportedly committed by uniQure and specific officials or board members of the company. This litigation highlights concerns raised during a recent meeting with the U.S. Food and Drug Administration (FDA) regarding the company's investigational gene therapy AMT-130, intended for Huntington's disease.

On November 3, 2025, uniQure publicly communicated feedback obtained from the FDA, which raised doubts about the adequacy of data from their Phase I/II studies. These data were initially believed to support a Biologics License Application (BLA) for AMT-130. The company's statement indicated a drastic change in perspective from prior discussions held with the FDA, leading to uncertainty surrounding the timeline for the BLA submission. This unexpected shift contributed to a dramatic drop in uniQure's stock price, which plunged by 49.34%, closing at $34.29 per share following the announcement.

Investors affected by this downturn are advised to act promptly as they have until April 13, 2026, to petition the court to be appointed as Lead Plaintiffs in this class action. Interested parties can obtain the complaint and further details by visiting Pomerantz's official website or by reaching out directly via email or phone.

Pomerantz LLP, known for its expertise in corporate and securities class action litigation, has a longstanding history of representing investors. Founded over 85 years ago by Abraham L. Pomerantz, the firm has been instrumental in securing multimillion-dollar settlements for victims of financial misconduct. Their commitment to protecting investors' rights remains steadfast, as they navigate the complexities of such legal matters to ensure justice is served.

For those looking to join the class action or simply seeking more information, you can contact Danielle Peyton at Pomerantz LLP. They are committed to assisting investors in understanding their rights and exploring avenues for redress. The firm encourages anyone who has purchased uniQure securities during the specified class period to get in touch with them, as every voice matters in such essential legal proceedings.

In conclusion, this class action lawsuit against uniQure N.V. serves as a crucial reminder of the vigilance needed within the domain of investments, particularly when faced with possible misconduct by corporate entities. Affected investors are encouraged not to delay in seeking recourse and are advised to stay informed of the ongoing developments in this case. The landscape of securities law can be complex, but firms like Pomerantz LLP are dedicated to serving the best interests of investors as they navigate through distressing financial turmoils.